Nexavar (sorafenib) meets goal in thyroid cancer trial

FRANKFURT (Reuters) - German drugmaker Bayer said its cancer treatment Nexavar (sorafenib) reached a goal of improving the survival of patients with radioactive iodine (RAI) refractory differentiated thyroid cancer in a late-stage clinical trial.
Source: Modern Medicine - Category: Journals (General) Source Type: news